Kamada Ltd.
KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunizatioā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.14
Price+0.56%
$0.04
1Y
Price
Market Cap
$411.937m
Small
Price/Earnings 3y Avg5y Avg
20.4x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+22.0%
EBITDA Margin+11.3%
Net Profit Margin+14.5%
Free Cash Flow Margin+22.0%
EBITDA Margin+11.3%
Net Profit Margin+14.5%
Free Cash Flow MarginRevenue
$181.682m
+8.6%
1y CAGR+10.6%
3y CAGR+14.1%
5y CAGREarnings
$20.366m
+41.4%
1y CAGR+191.0%
3y CAGR+142.2%
5y CAGREPS
$0.35
+44.0%
1y CAGR+170.2%
3y CAGR+127.7%
5y CAGRBook Value
$259.387m
$383.021m
Assets$123.634m
Liabilities$11.641m
DebtDebt to Assets
3.0%
0.3x
Debt to EBITDAFree Cash Flow
$16.530m
-50.3%
1y CAGR+781.5%
3y CAGR+658.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company